| Literature DB >> 32992796 |
Lubov Tereshchuk1, Kseniya Starovoytova1, Olga Babich2,3, Lyubov Dyshlyuk4, Irina Sergeeva1, Valery Pavsky5, Svetlana Ivanova4,5, Alexander Prosekov6.
Abstract
Dietary supplementation based on sea buckthorn and rosehip oils with added chokeberry extract was studied. We added the dietary supplement to the feed mixtures for laboratory animals. The possible toxicological effects and hypocholesterolemic, hepatoprotective activity of the dietary supplement in vivo were studied. After the observation period (6 weeks), no significant changes were found in the mass of organs and blood serum of laboratory animals (p > 0.05). However, there was a decrease in hypercholesterolemic indicators. Regular consumption of sea buckthorn and rosehip oils with added chokeberry extract (dietary supplement "ESB-1") by laboratory animals inhibited the activity of liver enzymes and increased the antioxidant activity of blood serum (after the subcutaneous injection of sunflower oil/oil solution of carbon tetrachloride) but was not sufficient to bring them to physiological standards. The hypocholesterolemic and antioxidant properties of our dietary supplement already allow us to consider it a component of functional food products or a dietary supplement base. However, the full range of its biologically active properties, including the hepatoprotective function and regulation of metabolic disorders, has not been studied yet, which sets the direction of further research in vivo models and clinical practice to confirm its effectiveness in humans.Entities:
Keywords: antioxidant activity; chokeberry; dietary supplement; hepatoprotective effects; hypolipidemic; sea buckthorn and rosehip oils
Mesh:
Substances:
Year: 2020 PMID: 32992796 PMCID: PMC7600764 DOI: 10.3390/nu12102941
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Active substances in the “ESB-1” dietary supplement (per one 2.0 g capsule).
| Active Substance | Content |
|---|---|
| PUFA ω-3, not less | 380 mg |
| including α-linolenic acid, not less than | 175 mg |
| PUFA ω-6, not less than | 380 mg |
| including linoleic acid, not less than | 265 m |
| γ-linolenic acid, not less than | 110 mg |
| ω-9 (oleic acid), not less than | 180 mg |
| essential phospholipids | 150 mg |
| α-tocopherol | 400 IU |
| β-carotene | 2 mg |
| rutin | 50 mg |
ESB—Extract of Siberian Berries.
Feed mixture recipes (g/kg of feed).
| Ingredients | Feed Mixture | ||||||
|---|---|---|---|---|---|---|---|
| No. 1 | No. 2 | No. 3 | No. 4 | No. 5 | No. 6 | No. 7 | |
| Corn starch | 510.7 | 509.7 | 508.6 | 506.5 | 456.5 | 458.7 | 454.5 |
| Dextrinate corn starch | 155.0 | 155.0 | 155.0 | 155.0 | 155.0 | 155.0 | 155.0 |
| Casein | 145.0 | 145.0 | 145.0 | 145.0 | 145.0 | 145.0 | 145.0 |
| Saccharose | 90.0 | 90.0 | 90.0 | 90.0 | 90.0 | 90.0 | 90.0 |
| Soybean oil | 50.0 | 50.0 | 50.0 | 50.0 | 10.0 | 10.0 | 10.0 |
| Ghee | - | - | - | - | 90.0 | 90.0 | 90.0 |
| AIN-93M (mixture of mineral salts) | 35.0 | 35.0 | 35.0 | 35.0 | 35.0 | 35.0 | 35.0 |
| AIN-93-VX (vitamin mix) | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| L-cysteine | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 |
| Choline bitartrate | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
| Cholesterol | - | - | - | - | - | 2.0 | 2.0 |
| “ESB-1” dietary supplement | - | 1.0 | 2.1 | 4.2 | 4.2 | - | 4.2 |
| 2-tert-butylhydroquinone in soy oil, mg | 8.0 | 8.0 | 8.0 | 8.0 | 8.0 | 8.0 | 8.0 |
AIN-93-VX, Vitamin Mix and AIN-93M, Mixture of Mineral Salts (MP Biomedical LLC, Santa Ana, CA, USA) are components of the recommended diet for rats and mice in scientific research.
Experimental design.
| Group | Number of Animals | Subcutaneous Injection | Diet |
|---|---|---|---|
| I | 15 | - | No. 1 |
| II | 15 | - | No. 2 |
| III | 15 | - | No. 3 |
| IV | 15 | - | No. 4 |
| V | 15 | - | No. 5 |
| VI | 15 | - | No. 6 |
| VII | 15 | - | No. 7 |
| VIII | 15 | Sterile refined and deodorized sunflower oil, 1 mL/kg of weight | No. 1 |
| IX | 15 | Oil solution of carbon tetrachloride, 1 mL/kg of weight | No. 1 |
| X | 15 | Oil solution of carbon tetrachloride, 1 mL/kg of weight | No. 4 |
Figure 1Biochemical and hematological indices of blood of animals from groups I–VII: 1—Cholesterol, mmol/L; 2—Triglycerides, mmol/L; 3—Bilirubin, μmol/L; 4—Number of leukocytes, g/L; 5—Hematocrit, L/L (bars in graphs indicate the SE of 15 replicates). Values with «*» do differ significantly (p > 0.05).
Figure 2Biochemical and hematological indices of blood of animals from groups I–VII: 6—Urea, mmol/L; 7—ALT, U/L; 8—AST, U/L; 9—Globulins, g/L; 10—Red blood cell count, g/L; (bars in graphs indicate the SE of 15 replicates).
Figure 3Biochemical and hematological indices of blood of animals from groups I–VII: 11—Total protein, g/L; 12—Albumin, g/L; 13—Creatinine, μmol/L; 14—Hemoglobin level, g/L; 15—Platelet count, g/L; 16—Average concentration hemoglobin in the erythrocyte, g/L (bars in graphs indicate the SE of 15 replicates).
Indicators of oxidative processes in the liver and blood serum antioxidant activity of laboratory animals.
| Duration of Incubation, after Subcutaneous Administration of Oil/Oil Solution of Carbon Tetrachloride, h | Groups | |||
|---|---|---|---|---|
| I | VIII | IX | X | |
|
| ||||
| Control | 208.92 ± 1.92 a | - | - | - |
| 24 | - | 234.67 ± 1.94 a | 463.98 ± 3.02 a | 265.47 ± 1.92 a |
| 48 | - | 243.02 ± 1.93 a | 508.57 ± 2.97 a | 304.31 ± 1.92 a |
| 72 | - | 266.04 ± 2.00 a | 586.12 ± 3.17 a | 316.22 ± 1.92 a |
|
| ||||
| Control | 9.24 ± 0.17 a | - | - | - |
| 24 | - | 11.03 ± 0.32 a | 32.76 ± 0.63 a | 15.06 ± 0.18 a |
| 48 | - | 41.97 ± 0.34 b | 54.22 ± 0.38 b | 20.04 ± 0.23 b |
| 72 | - | 21.34 ± 0.24 b | 72.18 ± 0.51 b | 23.11 ± 0.22 b |
|
| ||||
| Control | 8.36 ± 0.21 a | - | - | - |
| 24 | - | 10.51 ± 0.32 a | 23.18 ± 0.42 b | 12.23 ± 0.72 a |
| 48 | - | 47.46 ± 0.54 b | 42.44 ± 0.38 b | 22.46 ± 0.78 b |
| 72 | - | 25.84 ± 0.57 b | 47.36 ± 0.45 b | 25.47 ± 0.45 b |
|
| ||||
| Control | 3.31 ± 0.16 a | - | - | - |
| 24 | - | 3.95 ± 0.21 b | 4.23 ± 0.21 b | 3.27 ± 0.17 a |
| 48 | - | 6.86 ± 0.33 b | 8.46 ± 0.43 b | 3.43 ± 0.17 a |
| 72 | - | 6.92 ± 0.34 b | 11.18 ± 0.57 b | 3.66 ± 0.17 a |
|
| ||||
| Control | 41.7 ± 4.2 a | - | - | - |
| 24 | - | 50.0 ± 5.1 b | 53.4 ± 5.4 b | 40.8 ± 4.1 a |
| 48 | - | 58.7 ± 5.8 b | 65.0 ± 6.6 b | 44.3 ± 4.3 a |
| 72 | - | 63.7 ± 6.3 b | 78.7 ± 7.9 b | 47.1 ± 4.6 a |
|
| ||||
| Control | 5.65 ± 0.56 a | - | - | - |
| 24 | - | 4.56 ± 0.55 a | 3.13 ± 0.32 b | 5.75 ± 0.57 a |
| 48 | - | 4.11 ± 0.51 a | 2.75 ± 0.27 b | 5.36 ± 0.54 a |
| 72 | - | 3.99 ± 0.51 a | 2.00 ± 0.22 b | 5.10 ± 0.50 a |
The data are expressed as mean ± SE (n = 15). Values followed by different letters in a line have considerable differences (p > 0.05) by LSD post-hoc test. I group—without subcutaneous administration; feed mixture No. 1; VIII group—subcutaneous oil administration; feed mixture No. 1; IX group—subcutaneous oil solution administration; feed mixture No. 1; X group—subcutaneous oil solution administration; feed mixture No. 4. MDA: malondialdehyde; LSD method – Least Square Difference method of statistics. TE: tocopherol equivalent.